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COMPLEMENT AND 
GRANULOCYTE ACTIVATION 
IN TWO DIFFERENT TYPES 
OF HEPARINIZED 
EXTRACORPOREAL 
CIRCUITS 
Complement and granulocyte activation were studied in cardiopulmonary 
bypass circuits completely coated with either end-attached covalent-bonded 
heparin, the Carmeda BioActive Surface, or with the Duraflo II bonded 
heparin, in combination with reduced systemic heparinization (activated 
clotting time > 250 seconds). The control groups were perfused with uncoated 
circuits and full heparin dose (activated clotting time > 480 seconds). 
Altogether 67 patients undergoing elective first-time myocardial revasculariza- 
tion were investigated, having extracorporeal perfusion with a Duraflo lI 
coated circuit (n = 17), an identical but uncoated circuit (n = 17), a Carmeda 
coated circuit (n = 17), or an equivalent uncoated circuit (n = 16). During 
cardiopulmonary b pass, the C3 activation products C3b, iC3b, and C3c 
(C3bc) and the terminal SC5b-9 complement complex increased markedly in 
all four groups compared with baseline, but significantly less in the two coated 
groups than in their control groups. Additionally, a significantly lower concen- 
tration of C3bc was observed in the Carmeda coated group, with maximal 
increase of median 28 AU/ml compared with 50 AU/ml in the Duraflo II coated 
group (p = 0.003). Similarly, in the Carmeda coated group, the maximal 
increase of terminal complement complex was considerably ower (0.8 AU/ml) 
than the levels recognized in the Duraflo II coated group (2.4 AU/ml) (p < 
0.001). The release of the granulocyte activation enzymes myeloperoxidase and 
lactoferrin increased from the beginning of the operation, with peak levels at 
the end of bypass. A significant reduction of lactoferrin release was recognized 
when comparing the coated groups with the control groups. The difference 
between the two coated groups (Carmeda 229/tg/L; Duraflo II 332 #g/L; p = 
0.05) was marginally significant. For myeloperoxidase, no significant differ- 
ences were observed between the coated and uncoated groups. In conclusion, 
both types of heparin-coated circuits reduced complement activation and 
release of lactoferrin, but the Carmeda circuit proved to be more effective than 
the Duraflo II equipment. (J THORAC CARDIOVASC SURG 1995;110:1623-32) 
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B inding of heparin to surfaces in contact with blood during cardiopulmonary b pass (CPB) has 
been shown to reduce activation of biologic cas- 
cades] -5 This indication of improved hemocompat- 
From the Department of Cardiac Surgery and Anesthesiology, Oslo 
Heart Center, Oslo, Norway"; the Department of Immunology 
and Transfusion Medicine, Nordland Central Hospital, and 
University of Tromso, Norwayb; Surgical Department A, The 
National Hospital, Osto, Norway'; and the Department of Clin- 
ical Chemistry, Uppsala University Hospital, Uppsala, Sweden. d 
Received for publication Dec. 23, 1994. 
Accepted for publication April 6, 1995. 
Address for reprints: Eivind Ovrum, MD, Oslo Heart Center, 
Pilestredet 32, 0027 Oslo, Norway. 
ibility may contribute to decrease the risk of post- 
perfusion injury. < v In addition, heparinized circuits 
have allowed reduced doses of systemic heparin, 
with the potential benefits of reduced postoperative 
bleeding and less need for protamine) '  9 
Heparin can be attached to polymers with various 
ionic preparations or by covalent binding to the 
surface] ° At the present ime, two different ypes of 
heparinized extracorporeaI circuits are available for 
clinical use. The Duraflo II surface (Baxter Health- 
care Corp., Bentley Laboratories Division, Irving 
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Tab le  I. Demographic data and operative details o f  the four groups* 
MedianO'ange) 
Duraflo H coated Duraflo II control 
Clinical parameters (n = 17) (n = 17) 
CBAS coated CBAS control 
(n = 17) (n = 16) 
Age (yr) 62 (47-73) 68 (44-74) 
Female/male 3/14 5/12 
Weight (kg) 76 (54-105) 76 (60-105) 
Ejection fraction (%) 68 (56-89) 73 (55-86) 
Internal mammary artery graft (patients) 17/17 17/17 
No. of distal anastomoses 4 (3-5) 4 (2-5) 
Extracorporeal time (rain) 43 (34-53) 46 (26-59) 
Ischemic time (rain) 24 (15-34) 25 (16-36) 
Lowest hematocrit value on bypass (%) 24 (19-30) 23 (19-25) 
66 (40-72) 62 (48-72) 
1/16 2/14 
79 (65-96) 83 (49-109) 
72 (56-93) 70 (48-86) 
17/17 16/16 
4 (2-6) 4 (2-6) 
47 (29-70) 51 (28-69) 
27 (17-50) 31 (16-46) 
23 (20-26) 23 (19-27) 
*No significant intergroup differences were detected. 
Calif.) binds heparin partly ionically by means of a 
proprietary process. 1° The Carmeda BioActive Sur- 
face (CBAS, Medtronic, Inc., Minneapolis, Minn.) 
covalently binds end point-attached egraded hep- 
arin. u Reduced complement  and granulocyte acti- 
vation has been demonstrated individually for both 
systems, 2-5'12 although most reports have been 
based on results in which only the oxygenators and 
tubings were heparinized. However,  comparison of 
the two systems with regard to degree of activation 
of b iomarkers has not previously been reported. 
The purpose of the present study was to compare 
the effects of the CBAS system and the Duraf lo I I  
circuit on the most relevant complement  markers 
(C3 activation products and terminal complement  
complex [TCC]), and the granulocyte activation as 
assessed by release of myeloperoxidase and lacto- 
ferrin, in patients undergoing elective coronary ar- 
tery bypass operations. 
Pat ients  and  methods  
Patients admitted for first-time lective coronary artery 
bypass grafting with two- or three-vessel disease were 
eligible for the study. They had a low operative risk 
profile. Urgent operation was a cause for exclusion, as 
were redo operations, age more than 75 years, and 
impaired left ventricular function. Neurologic disorders 
and liver and renal failure were also reasons for exclusion. 
Anticoagulation or antiplatelet therapy was discontinued 
7 days before the operation in all patients. 
Informed consent was obtained from all patients and 
the study protocol was approved by the regional ethical 
committee. All operations were performed by one of two 
surgeons (E.O., G.T.). 
For the Duraflo II part of the study, 34 patients were 
prospectively randomized to have CPB with a heparin- 
coated circuit (coated group) or with an uncoated but 
otherwise identical circuit (control group). No visual 
differences between the two extracorporeal circuits were 
present, and the surgical team was blinded to the random- 
ization. 
Duraflo II group (n = 17). All surfaces in contact with 
blood were coated with a water-insoluble heparin com- 
plex. The circuit included silicone and polyvinylchloride 
tubings connected to a hard-shell cardiotomy reservoir 
(DII BCR 3500, Baxter Bentley), a soft-shell venous 
reservoir (DII BMR-1900, Baxter Bentley), a woven hol- 
low polypropylene-fiber membrane oxygenator (Univox 
Gold; Baxter Bentley, surface area 1.80 m2), and a 25/xm 
arterial filter (DII AF-1025, Baxter Bentley). Systemic 
heparin (Nycomed Pharma, Oslo, Norway) was given in a 
bolus dose of 100 IU/kg. Activated clotting time (ACT) 
(HemoTec, Inc., Englewood, Colo.) should exceed 250 
seconds before institution of CPB. The dose of protamine 
sulfate for neutralization of heparin was 1.3 mg/100 IU 
heparin. The extracorporeal bypass circuit was discon- 
nected before administration of protamine. 
Duraflo II control group (n = 17). The extracorporeal 
circuit was uncoated but otherwise identical to the hepa- 
rin-eoated equipment. Heparin was administered in a 
dose of 400 IU/kg, and the ACT exceeded 480 seconds 
before CPB was begun. The protamine/heparin atio was 
similar to that in the coated group. 
The patients in whom the CBAS system was used were 
entered in the study immediately after the Duraflo II 
series had been terminated. The protocol for patient 
selection and study design were exactly the same as for the 
Duraflo II series. 
CBAS group (n = 17). Every part of the extracorporeal 
equipment in contact with the patient's blood was coated 
with end-attached covalent-bonded heparin. The circuit 
included polyvinylchloride tubings connected to a hard- 
shell cardiotomy reservoir (CB SK 1351, Medtronic), a 
collapsible venous reservoir bag (CB MVR 1600, Med- 
tronic), a woven hollow polypropylene-fiber membrane ox- 
ygenator (CB Maxima Plus 3380, Medtronic, surface area 
2.0 m2), and a 20/xm arterial filter (CB M-20, Medtronic). 
As for the Duraflo II coated group, systemic heparin was 
given in a bolus dose of 100 IU/kg and ACT exceeded 250 
seconds before CPB. 
CBAS control group (n = 16). The extracorporeal 
circuit was uncoated but otherwise identical to the coated 
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Table I I . Heparin and protarnine sulfate doses in the four groups 
Median (range) 
Duraflo II coated Duraflo H control CBAS coated CBAS control 
Doses (n = 17) (n = 17) (n = 17) (n = 16) 
Heparin/body weight (lUNg) 
Protaminc sulfate/body weight (mg/kg) 
Protamine/heparin 
130 (105-179)* 450 (350-620) 150 (104-213)* 426 (407-522) 
1.7 (1.4-2.4) 5.4 (5,1-7.1) 1.7 (1.3-2.8) 5.4 (5.0-6.8) 
1.32 (1.25-1.59) 130 (1,24-1.43) 1.29 (0.88-1.50) 1,29 (1.06q.47) 
*Between the coated groups there was significant difference inthe heparin doses (p < 0.05). 
equipment, and the heparin and protamine administration 
was similar to that used in the Duraflo II control group. 
In all groups, additional heparin was given if the ACT was 
below the lower limit. The postoperative ACT should be less 
than 130 seconds, and protamine was added if necessary. 
Operation and blood conservation. Extracorporeal cir- 
culation was performed with the use of a St6ckert roller 
pump with the pulsatile flow control device (PFC III, 
St6ckert Instrumente GmbH, Munich, Germany). Mild 
hypothermia (blood temperature, 32 ° C) was instituted 
immediately after CPB was begun. The heart-lung ma- 
chine was primed with 2000 ml of Ringer's acetate, and 
hemodilution was even more accentuated by removal of 
autologous blood for blood conservation, ~3which aimed 
at an intraoperative h matocrit value of more than 22%. 
The ventilation of the lungs was terminated uring CPB 
and reinstituted a few minutes before conclusion of CPB. 
Myocardial protection consisted of antegrade administra- 
tion of crystalloid cardioplegic solution (St. Thomas' Hospi- 
tal No. 2) and topical cooling with ice slush. Cardiotomy 
suction was used during the entire period of heparinization. 
Anticoagulation was reversed with protamine sulfate. The 
mediastinal shed blood was autotransfused hourly in a closed 
system up to 18 hours after the operation. 
ACT was measured before the operation, after heparin 
administration, before CPB, 10 minutes after the start of 
CPB, at 20-minute intervals during CPB, after protamine 
administration, and 2 hours after the operation. 
Test blood sampling. Samples of blood treated with 
ethylenediaminetetraacetic ac d were drawn from the 
central venous cannula t the following intervals: (1) after 
induction of anesthesia; (2) immediately after institution 
of CPB; (3) after release of the aortic crossclamp; (4) at 
the end of CPB, after the onset of lung ventilation; (5) 2 
minutes after administration of protamine; (6) 2 hours 
after the operation; and (7) 18 hours after the operation. 
All samples were immediately cooled on ice and cen- 
trifuged, and plasma was stored at -70 ° C until assayed in 
one batch for all groups. The analyses were performed by 
investigators blinded with regard to allocation of the 
patients to the four groups. 
Analysis. C3 activation was measured in a double- 
antibody enzyme immunoassay. 14 The polystyrene plates 
were coated with a mouse monoclonal antibody (bH6) 
specific for a C3 neoepitope xpressed in C3b, iC3b, and 
C3c, but not in the native C3 component. The concentra- 
tion of the SC5b-9 TCC was quantified in a similar enzyme 
immunoassay with a mouse monoclonal antibody (aEll)  
specific for a neoepitope xpressed only in activated C9. ss 
C3bc and TCC are indicated as arbitrary units (AU) per 
milliliter, referred to a standard of zymosan-activated 
serum defined to contain 1000 AU/ml. 
Myeloperoxidase was analyzed according to instruc- 
tions given by the manufacturer (Pharmacia Diagnostics, 
Uppsala, Sweden), and lactoferrin was analyzed in plasma 
by radioimmunologic techniquesJ 6 
The total plasma concentration fheparin was analyzed 
as a complex with the antithrombin present in plasma 
(Coatest Heparin, Chromogenix, M61ndal, Sweden). 
Statistics. The four groups were compared by means of 
the Kruskal-Wallis test for continuous variables. Discrete 
variables were treated by means of contingency tables, 
with Yates' correction and Fisher's test when one of the 
expected cell values was less than 5. For the serial 
measurements of C3bc, TCC, lactoferrin, and myeloper- 
oxidase, the sample points were related to the progress of 
the operation and differed in each patient. Therefore 
comparisons at each sample point were not considered 
relevant. Hence the values were treated individually for 
each patient, the maximal increase being calculated as the 
difference between the individual peak value (regardless 
sample point) and the value obtained immediately after 
the start of CPB. The summary measurements in each 
group were compared by means of the Mann-Whitney 
test. 17 Analysis of the time-dependent changes within 
each group were done by means of the paired Student's t 
t8 test and the Wilcoxon paired test. The values are 
presented as medians with quartiles or range when indi- 
cated. Ap  value less than 0.05 was considered significant. 
Results 
The demographic data are shown in Table I. No 
significant differences in any parameters were ob- 
served. Higher amounts of heparin and more sup- 
plemental doses were required in the CBAS coated 
group than in the Duraflo II  coated group (p < 0.05) 
to achieve the lower limit of ACT  (Table II). 
Despite this fact, the ACTs during CPB were signif- 
icantly higher in the Duraflo II  coated group (p < 
0.01) (Fig. 1). This difference was confirmed by 
estimation of total plasma heparin, which showed 
higher levels in the Duraflo I I  coated group during 
CPB (Fig. 2). An index of the summary values of the 
heparin concentration during CPB/systemic heparin 
dose revealed a highly significant difference between 
the groups (p < 0.001). The actual doses of  heparin 
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Fig. 1. Perioperative ACT in the two heparin-coated groups. Significant differences (*p < 0.001, **p < 
0.01) were observed uring CPB. 
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Fig. 2. Perioperative plasma concentration of heparin in the two heparin-coated groups. X-clamp, 
Crossclamp. 
in the coated groups were reduced to approximately 
30% of the doses in the control groups. 
The postoperative parameters such as mediastinal 
drainage, hemoglobin concentration at discharge, 
and kidney function were similarly favorable in all 
four groups, with no significant intergroup differ- 
ences (Table III). All patients urvived. 
The mean hematocrit values during CPB and 
body weights were similar in the groups, and all 
figures for the activation products are given uncor- 
rected for hemodilution. 
C3 activation products (C3bc). The C3 activation 
products C3b, iC3b, and C3c increased markedly in 
all groups compared with baseline values (p < 
0.001), reaching a peak level at the end of the 
operation (Fig. 3). The levels were significantly 
lower in the CBAS coated group than in the CBAS 
control group (p = 0.01) or in either Duraflo II
group. The maximal increase of C3bc after CPB 
reached a median of 28 AU/ml (18 to 40 AU/ml) in 
the CBAS group compared with the median 50 
AU/ml (37 to 58 AU/ml) in the Duraflo II group 
(p = 0.003) (see Fig. 7). In fact, there were no 
significant differences between the Duraflo II coated 
group and the uncoated CBAS control group. At 18 
hours after the operation, the concentration of C3bc 
had returned to baseline levels in all groups. 
TCC. The TCC concentration i  the CBAS group 
increased slightly and reached borderline signifi- 
cance compared with baseline (p = 0.048). In the 
Ovn~rn et al. 1627 
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Fig. 3. Time-dependent plasma concentration of the C3 activation products in all groups. X-clamp, 
Crossclamp. 
Table III. Postoperative data of the four groups* 
Median (range) 
Duraflo H coated Duraflo H control CBAS coated CBAS control 
Postoperative data (n = 17) (n = 17) (n = 17) (n = 16) 
Mediastinal drainage (ml) 
Homologous transfusions (blood/plasma) 
Preop. hemoglobin concentration (gin/L) 
Hemoglobin concentration at discharge (gm/L) 
Clinical results: 
Intubated postop. (hr) 
Maximal postop, creatinine concentration (retool/L) 
Perioperative myocardial infarction 
Mortality 
620 (405-830) 675 (355-1305) 615 (265-1035) 628 (420-1360) 
0 0 0 2 
148 (118-178) 146 (125-176) 145 (129-169) 145 (127-165) 
121 (109-162) 122 (96-142) 125 (94-142) 116 (108-128) 
1.0 (0.5-2.3) 1.6 (08-3.3) 1.5 (0.3-3.0) 16 (0.8-3.3) 
102 (81-159) 97 (79-138) 104 (84-132) 108 (87-142) 
0 0 0 1 
0 0 0 0 
*No significant intergroup differences were detected. 
Duraflo II group, however, and in the two control 
groups, a highly significant increase comparedwith 
the baseline level was recognized (p < 0.001) (Fig. 
4). In the CBAS group, the maximal increase of 
TCC during CPB (see Fig. 7) was a median of 0.8 
AU/ml (0.6 to 1.2 AU/ml) compared with a median 
of 2.4 AU/ml (1.8 to 2.7 AU/ml) in the Duraflo II 
group (p < 0.001). As with C3bc, there were no 
significant differences between the Duraflo II coated 
group and the uncoated CBAS control group. The 
TCC level returned to preoperative values the day 
after the operation. 
Lactoferrin. An increase of lactoferrin release 
started from the beginning of the operation, con- 
tinuing during CPB to reach a significantly higher 
level in all groups compared with baseline levels 
(p < 0.001) (Fig. 5). The concentrations in the 
heparin-coated groups were considerably ower than 
those of their respective control groups (p < 0.01) 
(see Fig, 7). The maximal release of lactoferrin in 
the CBAS group was 229/xg/L (182 to 341/*g/L) and 
marginally less than the Duraflo II level of 332/,g/L 
(235 to 451/,g/L) (p = 0.05). In both control groups, 
a sudden and significant (p < 0.001) decrease of the 
lactoferrin concentration was seen 2 minutes after 
protamine administration, with another increase 2 
hours later. 
Myeloperoxidase. As for lactoferrin, the release 
of myeloperoxidase increased in all groups from the 
start of the operations and reached threefold the 
baseline level at the end of CPB (p < 0.001) (Fig. 6). 
No significant differences were noted between the 
coated groups and their respective control groups 
(Fig. 7). A decrease in the levels was observed after 
protamine administration, but to a much lesser 
degree than for lactoferrin. 
AU/ml 
Ovrum et al. 
The Journal of Thoracic and 
Cardiovascular Surgery 
December 1995 
CBAS coated 
tI-Duraflo 1I coated ~ "~ 
-*- CBAS control ~ 
1628 
I I I ¸ i I I 
Preop X-clamp off After protamine 18 hrs postop 
Start CPB End CPB 2 hrs postop 
Fig. 4. Time-dependent plasma concentration of SC5b-9 TCC in all groups. X-clamp, Crossclamp. 
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Fig. 5. Time-dependent plasma concentration of l ctoferrin in all groups. X-clamp, Crossclamp. 
The summary results of the most relevant inter- 
group differences in maximal concentrations of the 
activation products are given in Table IV. 
Discussion 
Heparin coating of nonendothelial surfaces in 
contact with blood was primarily initiated to im- 
prove thromboresistance 19 but has been docu- 
mented to reduce activation of several biologic 
cascades.2-4, 122o Two different processes of coating 
extracorporeal circuits with immobilized heparin 
have been developed and are available for clinical 
use. The CBAS process is based on depositing a
polymer coating, polyethylenimine, onto various 
types of surfaces. Heparin fragments, prepared from 
the degradation of heparin in nitrous acid, are then 
end-point attached and covalently bonded to the 
polymer. 11 The Duraflo II process is based on the 
concept of modifying the physiochemical properties 
of unfractionated heparin with a proprietary binding 
agent, which has high affinity to a variety of synthetic 
surfaces. 1°Direct comparison f blood compatibility 
of the two differently heparinized circuits has not 
previously been reported. 
Until recently, only the oxygenator and tubings 
could be coated with heparin, and most clinical 
studies have been carried out under partly experi- 
mental circumstances. In the present study, the 
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Fig. 7. Maximal increase of the activation markers during the operation in the four groups. The levels 
were significantly lower in the CBAS group than in the Duraflo lI group for C3 activation products (C3bc) 
(*p = 0.003), and for the SC5b-9 TCC (**p < 0,001). There were marginal differences for lactoferrin 
(Lacto) (p = 0.05), but no difference for myeloperoxidase (MPO). See Table IV for further intergroup 
differences. Median values with quartiles. 
effects on bioactive markers could be investigated in
a situation in which all surfaces of the extracorpo- 
real circuit in contact with blood were coated with 
heparin, including cannulas, lines, filters, and the 
cardiotomy reservoir. 
Significant reduction of complement activation 
was demonstrated with both heparin-coated circuits 
compared with their uncoated controls. This obser- 
vation supports several previous studies of partly 
heparin-coated circuits 2-5'21 and is generally ac- 
cepted as evidence of the improved hemocompat- 
ibility when immobilized heparin is attached to 
artificial surfaces. However, two main distinctions 
were recognized when the two differently hepa- 
rinized extracorporeal circuits were compared: 
First, the patients in the Duraflo II group re- 
quired less heparin than the CBAS group to reach 
the lower limit of ACT. Despite this fact, the plasma 
concentrations of total circulating heparin during 
CPB were significantly higher in the Duraflo II 
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Table IV. The percentage reduction of maximal concentrations of the activation products, comparing relevant 
groups 
C3bc TCC Lacto MPO 
Groups compared % p Value % p Value % p Value % p Value 
CBAS coated vs. Duraflo II coated 44 0.003 67 <0.001 31 0.05 
CBAS control vs. Duraflo control 39 0.009 54 0.02 -9.9 NS 
Duraflo II coated vs. Duraflo II control 46 0.02 41 0.004 43 0.002 
CBAS coated vs. CBAS control 37 0.01 58 <0.001 65 <0.001 
31 NS 
37 0.04 
20 NS 
23 NS 
C3bc, C3 activation products; TCC, terminal complement complex; Lacto, lactoferriu; MPO, myetoperoxidase; NS, not significant. 
group. This difference is assumed to be due to 
leaching heparin to the circulation from the Duraflo 
II surface, and it agrees with an in vitro blood 
recirculation loop test of coated arterial filters. 1° 
About 10% of the bonded heparin was demon- 
strated to be circulating shortly after CPB but 
remained stable at this level for 2 hours. 
Second, the patients in the Duraflo II group 
showed significantly higher concentrations of com- 
plement activation products than the CBAS group, 
both at the intermediate C3 level and the end of the 
cascade, as assessed by the concentration of the 
SC5b-9 TCC. In the CBAS coated group, the levels 
of C3 activation products and TCC were lower than 
those of the Duraflo II coated group, 44% and 67%, 
respectively. The same trend was observed for re- 
lease of lactoferrin. This evidence of different de- 
grees of hemocompatibility may have several rea- 
sons, and interpretations of the data are not 
obvious. Whether leaching of heparin from the 
coated Duraflo II surface, in contrast to the more 
stable CBAS coating, tl may change the bioactive 
layer with regard to the surface activation remains to 
be proved in experimental studies. 
One striking observation, however, was that the 
formation of C3bc and TCC was significantly less 
prevalent in the uncoated CBAS control group than 
in the uncoated Duraflo II group. The magnitude of 
the surface areas in contact with blood could poten- 
tially have some influence, but the surfaces were 
similar in all oxygenators, or even smaller in the 
Duraflo II groups. These facts clearly demonstrate 
that the construction and design of the extracorpo- 
real equipment have a major impact on activation of 
the complement cascade, whether the surfaces are 
coated with biologic substances or not. Similar con- 
clusions were drawn in a study of complement 
activation i  an in vitro study of six different bubble 
and membrane oxygenators. 22 Therefore the re- 
duced activation of complement and granulocytes 
recognized in the CBAS coated group compared 
with the Duraflo II group is likely due to a combi- 
nation of different construction designs of the extra- 
corporeal components and the process for immobi- 
lizing heparin to the surfaces. 
These findings illustrate the dilemma ofthe study, 
when investigating two different coating processes 
applied to two different ypes of circuits. For the 
true effects on blood compatibility of the differently 
heparinized surfaces to be evaluated, efinite stud- 
ies ideally require "crossover" heparin coating of 
the two extracorporeal systems. This is probably 
incompatible with proprietary interests of the man- 
ufacturers. So far, the present instruments are the 
only circuits available for clinical purposes; conse- 
quently, documentations of differences in perfor- 
mance and impact on biologic ascades are relevant. 
Activation of complement is associated with 
activation of granulocytes. 23 Release of cytolytic 
enzymes contributes to he adverse ffects of extra- 
corporeal circulation. 24For the activation of granu- 
locytes to be monitored, the r lease of the glyco- 
proteins lactoferrin and myeloperoxidase were 
assessedY Both proteins are mediators of the in- 
flammatory response. In the present study, lacto- 
ferrin levels increased rapidly during CPB in all 
groups. The release was significantly reduced in 
both heparin-coated groups compared with their 
control groups. This corresponds with other re- 
ports.4,12 A marginal difference was observed in 
favor of less release in the CBAS group than in the 
Duraflo II group. 
Myeloperoxidase r lease did not differ between 
the two heparin-coated groups or by comparison 
with their control groups. This observation is in 
contrast to other reports. 4'12 However, inasmuch as 
the maximal effects of heparin coating on myeloper- 
oxidase release were demonstrated to occur late 
during CPB, 4' 12 the limited extracorporeal times in 
our series may explain the differences. Significantly 
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less release was seen in the CBAS control group 
than in the Duraflo II control group, again indicat- 
ing the impact of the design of the circuits. 
No evidence of decreased postoperative ble ding 
was seen when heparin dosages were lowered, as 
reported by others, s'9 The main reason is probably 
due to the limited number of patients in each group, 
which precludes any significant conclusions with 
regard to clinical effects. Moreover, the mediastinal 
drainage was modest in all groups, including the 
control groups, and this may mask the influence of 
the heparin-coated circuits. 
In summary, reduced activation of complement 
and granulocyte release of lactoferrin was demon- 
strated for both Duraflo II circuits and CBAS 
circuits used for CPB during coronary artery bypass 
operations. However, significantly less activation of 
the complement system was observed for the CBAS 
group, probably because of the different design of
the circuits and the alternative processes for binding 
heparin to surfaces. The clinical course was unevent- 
ful in all groups; however, the patients elected for 
the study were at low risk, and major complications 
or organ failures were not expected. The clinical 
impact of the different patterns of hemocompatibil- 
ity of the two types of heparinized circuits remains 
uncertain, but it may be assumed to have conse- 
quences in more critically ill patients and in situa- 
tions requiring long periods of extracorporeal circu- 
lation. 
We thank Hanne Halvorsen for excellent technical 
assistance and Hilde Fure for skillful assistance in analyz- 
ing the blood samples. 
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